ACTRN12608000013369尚未招募2 期
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response
Royal Women's Hospital0 个研究点目标入组 37 人开始时间: 2008年1月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 21 Years 至 o limit（—）
- 性别
- Female
入选标准
- •Rising CA125 (Rustin)
- •2 previous lines of chemotherapy
排除标准
- •Impending bowel obstruction
研究者
相似试验
进行中（未招募）
1 期
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer - TIREGadvanced/recurrent ovarian and endometrial cancerMedDRA version: 12.1Level: LLTClassification code 10057529Term: Ovarian cancer metastaticMedDRA version: 12.1Level: LLTClassification code 10066697Term: Ovarian cancer recurrentMedDRA version: 12.1Level: PTClassification code 10057529Term: Ovarian cancer metastaticMedDRA version: 12.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentMedDRA version: 12.1Level: LLTClassification code 10014734Term: Endometrial cancer metastaticMedDRA version: 12.1Level: LLTClassification code 10014736Term: Endometrial cancer recurrentMedDRA version: 12.1Level: PTClassification code 10014734Term: Endometrial cancer metastaticMedDRA version: 12.1Level: PTClassification code 10014736Term: Endometrial cancer recurrentEUCTR2010-023457-11-BEZ Leuven37
已完成
不适用
Immunological aspects of combined chemotherapy and immunotherapy with HPV16 E6/E7 Synthetic Long Peptide vaccination in patients with advanced cervical cancer.cancer of the cervix10038594cervical cancerNL-OMON36470eids Universitair Medisch Centrum18
进行中（未招募）
不适用
The influence of immunotherapy and chemotherapy accompanying endurance training on incidence and severity of cognitive deficits as well as other therapy-induced side effects and complications in oncological patients. A randomized controlled trialDIVERSEC00-C75Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissueDRKS00011390niversitäres Centrum für Tumorerkrankungen (UCT) FrankfurtKrankenhaus NordwestKlinik für Onkologie und Hämatologie2
招募中
1 期
Adoptive immune therapy of chemotherapy-refractory CMV-infection with Streptamer-selected T-cells after allogeneic bone marrow- or peripheral blood stem cell transplantatioB25.9Cytomegaloviral disease, unspecifiedDRKS00000205Stage Pharmaceuticals GmbH30
终止
2 期
EMOTIV Trial - Enhancing Melanoma Outcomes using a Timed Immunotherapy VaccineAdvanced Stage IIIb/c and IV MelanomaCancer - Malignant melanomaACTRN12612001069842Australian Melanoma Research Foundation20